Study of Tolerance to Oral Peanut

Cambridge University Hospitals NHS Foundation Trust22 enrolled

Overview

Open pilot study of peanut oral immunotherapy in 22 children with peanut allergy

Background Peanut allergy is severe and rarely resolves. Objective To test the efficacy and safety of a new oral immunotherapy protocol for peanut allergy. Method 22 peanut-allergic children will undergo oral challenge. Oral immunotherapy will be administered by gradual updosing with 2-weekly increments (8-38w) to 800mg protein (5 peanuts/day) followed by 30-weeks maintenance. Oral challenge will be repeated after 6 and 30 weeks maintenance.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Peanut Allergy

Interventions

Peanut oral immunotherapyDIETARY_SUPPLEMENT

Daily doses of peanut flour

Eligibility

Sex: ALLMin age: 7 YearsMax age: 17 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Peanut allergy defined by oral challenge Exclusion Criteria: * Major immunodeficiency

Locations (1)

Cambridge Biomedical Campus

Cambridge, Cambridgeshire, United Kingdom

Outcomes

Primary Outcomes

Pass/fail peanut challenge

Time frame: six months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.